Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Determinants of COVID-19 disease severity in patients with underlying rheumatic disease

Santos et al., Clinical Rheumatology, doi:10.1007/s10067-020-05301-2
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 92% Improvement Relative Risk HCQ for COVID-19  Santos et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 38 patients in Spain (March - June 2020) Lower mortality with HCQ (not stat. sig., p=0.19) c19hcq.org Santos et al., Clinical Rheumatology, Jul 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 417 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 102 treatments. c19hcq.org
Prospective study of 38 hospitalized rheumatic disease patients with COVID-19 in Spain, showing no mortality with existing HCQ use compared to 32% without, not reaching statistical significance. Authors also report on the use of HCQ/CQ after hospitalization. The prophylaxis and late treatment results are listed separately1,2.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 92.5% lower, RR 0.08, p = 0.19, treatment 0 of 7 (0.0%), control 10 of 31 (32.3%), NNT 3.1, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Santos et al., 27 Jul 2020, prospective, Spain, peer-reviewed, median age 78.4, mean age 75.3, 6 authors, study period 1 March, 2020 - 1 June, 2020. Contact: cristysieirosantos@gmail.com.
This PaperHCQAll
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
C Sieiro Santos, C Moriano Morales, E Díez Álvarez, C Álvarez Castro, A López Robles, T Perez Sandoval
Clinical Rheumatology, doi:10.1007/s10067-020-05301-2
Background Over the month of April, Spain has become the European country with more confirmed cases of COVID-19 infection, after surpassing Italy on April 2nd. The community of Castile and León in Spain is one of the most affected by COVID-19 infection and the province of León has a total of 3711 cases and 425 deaths so far. Rheumatic patients should be given special attention regarding COVID-19 infection due to their immunocompromised state resulting from their underlying immune conditions and use of targeted immune-modulating therapies. Studying epidemiological and clinical characteristics of patients with rheumatic diseases infected with SARS-CoV2 is pivotal to clarify determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Objectives To describe epidemiological characteristics of patients with rheumatic diseases hospitalized with COVID-19 and determine risk factors associated with mortality in a third level Hospital setting in León, Spain. Methods We performed a prospective observational study, from 1st March 2020 until the 1st of June including adults with rheumatic diseases hospitalized with COVID-19 and performed a univariate and multivariate logistic regression model to estimate ORs and 95% CIs of mortality. Age, sex, comorbidities, rheumatic disease diagnosis and treatment, disease activity prior to infection, radiographic and laboratorial results at arrival were analysed. Results During the study period, 3711 patients with COVID-19 were admitted to our hospital, of whom 38 (10%) had a rheumatic or musculoskeletal disease. Fifty-three percent were women, with a mean age at hospital admission of 75.3 (IQR 68-83) years. The median length of stay was 11 days. A total of 10 patients died (26%) during their hospital admission. Patients who died from COVID-19 were older (median age 78.4 IQR 74.5-83.5) than those who survived COVID-19 (median age 75.1 IQR 69.3-75.8) and more likely to have arterial hypertension (9 [90%] vs 14 [50%] patients; OR 9 (95% CI 1.0-80.8), p 0.049), dyslipidaemia (9 (90%) vs 12 (43%); OR 12 (95% CI 1.33-108), p 0.03), diabetes ((9 (90%) vs 6 (28%) patients; OR 33, p 0.002), interstitial lung disease (6 (60%) vs 6 (21%); OR 5.5 (95% CI 1.16-26), p 0.03), cardiovascular disease (8 (80%) vs 11 (39%); OR 6.18 (95% IC 1.10-34.7, p 0.04) and a moderate/high index of rheumatic disease activity (7 (25%) vs 6(60%); OR 41.4 (4.23-405.23), p 0.04). In univariate analyses, we also found that patients who died from COVID-19 had higher hyperinflammation markers than patients who survived: C-reactive protein (181 (IQR 120-220) vs 107.4 (IQR 30-150; p 0.05); lactate dehydrogenase ) vs 361 (IQR 250-450), p 0.03); serum ferritin (1026 (IQR 228.3-1536.3) vs 861.3 (IQR 389-1490.5), p 0.04); D-dimer (12,019.8 (IQR 843.5-25,790.5) vs 1544.3 (IQR 619-1622), p 0.04). No differences in sex, radiological abnormalities, rheumatological disease, background therapy or symptoms before admission between deceased..
References
Chen, Zhao, Qu, Chen, Xiong, Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients
Fadel, Morrison, Pharm, Vahia, Smith et al., 19 Management Task Force, Early Short Course Corticosteroids in Hospitalized Patients with COVID-19, Clin Infect Dis, doi:10.1093/cid/ciaa601
Favalli, Ingegnoli, Lucia, Cincinelli, Cimaz et al., COVID-19 infection and rheumatoid arthritis: faraway, so close!, Autoimmun Rev
Furst, The risk of infections with biologic therapies for rheumatoid arthritis, Semin Arthritis Rheum
Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217871
Goyal, Choi, Pinheiro, Clinical characteristics of Covid-19 in New York City, N Engl J Med Overseas Ed, doi:10.1056/NEJMc2010419
Graef, Liew, Putman, Simard, Sirotich et al., Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217480
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30185
Kim, Sparks, Liew, A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19, Ann Intern Med published online
Mahevas, Tran, Roumier, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Pan, Ye, Sun, Gui, Liang et al., Time Course of Lung Changes On Chest CT During Recovery From, Radiology
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA, doi:10.1001/jama.2020.6775
Yang, Feng, Yuan, Yuan, Fu et al., Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS, Diabet Med
{ 'indexed': {'date-parts': [[2022, 9, 11]], 'date-time': '2022-09-11T08:49:44Z', 'timestamp': 1662886184588}, 'reference-count': 14, 'publisher': 'Springer Science and Business Media LLC', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2020, 7, 27]], 'date-time': '2020-07-27T00:00:00Z', 'timestamp': 1595808000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2020, 7, 27]], 'date-time': '2020-07-27T00:00:00Z', 'timestamp': 1595808000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1007/s10067-020-05301-2', 'type': 'journal-article', 'created': {'date-parts': [[2020, 7, 27]], 'date-time': '2020-07-27T10:02:48Z', 'timestamp': 1595844168000}, 'page': '2789-2796', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 55, 'title': 'Determinants of COVID-19 disease severity in patients with underlying rheumatic disease', 'prefix': '10.1007', 'volume': '39', 'author': [ {'given': 'C. Sieiro', 'family': 'Santos', 'sequence': 'first', 'affiliation': []}, {'given': 'C. Moriano', 'family': 'Morales', 'sequence': 'additional', 'affiliation': []}, {'given': 'E. Díez', 'family': 'Álvarez', 'sequence': 'additional', 'affiliation': []}, {'given': 'C. Álvarez', 'family': 'Castro', 'sequence': 'additional', 'affiliation': []}, {'given': 'A. López', 'family': 'Robles', 'sequence': 'additional', 'affiliation': []}, {'given': 'T. Perez', 'family': 'Sandoval', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 7, 27]]}, 'reference': [ { 'key': '5301_CR1', 'doi-asserted-by': 'crossref', 'unstructured': 'Pan F, Ye T, Sun P, Gui S, Liang B, Li L et al (2020) Time Course of ' 'Lung Changes On Chest CT During Recovery From 2019 Novel coronavirus ' '(COVID-19) pneumonia. Radiology.:200370', 'DOI': '10.1148/radiol.2020200370'}, { 'key': '5301_CR2', 'doi-asserted-by': 'publisher', 'first-page': '327', 'DOI': '10.1016/j.semarthrit.2008.10.002', 'volume': '39', 'author': 'DE Furst', 'year': '2010', 'unstructured': 'Furst DE (2010) The risk of infections with biologic therapies for ' 'rheumatoid arthritis. Semin Arthritis Rheum 39:327–346', 'journal-title': 'Semin Arthritis Rheum'}, { 'key': '5301_CR3', 'doi-asserted-by': 'crossref', 'unstructured': 'Kim AHJ, Sparks JA, Liew JW et al (2020) A rush to judgment? Rapid ' 'reporting and dissemination of results and its consequences regarding ' 'the use of hydroxychloroquine for COVID-19. Ann Intern Med published ' 'online March 30', 'DOI': '10.7326/M20-1223'}, { 'key': '5301_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1033', 'DOI': '10.1016/S0140-6736(20)30628-0', 'volume': '395', 'author': 'P Mehta', 'year': '2020', 'unstructured': 'Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH ' 'Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine ' 'storm syndromes and immunosuppression. Lancet 395:1033–1034', 'journal-title': 'Lancet'}, { 'key': '5301_CR5', 'doi-asserted-by': 'crossref', 'unstructured': 'Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R ' '(2020) COVID-19 infection and rheumatoid arthritis: faraway, so close! ' 'Autoimmun Rev', 'DOI': '10.1016/j.autrev.2020.102523'}, { 'key': '5301_CR6', 'doi-asserted-by': 'publisher', 'unstructured': 'Goyal P, Choi JJ, Pinheiro LC et al (2020) Clinical characteristics of ' 'Covid-19 in New York City. N Engl J Med Overseas Ed. ' 'https://doi.org/10.1056/NEJMc2010419', 'DOI': '10.1056/NEJMc2010419'}, { 'key': '5301_CR7', 'doi-asserted-by': 'publisher', 'unstructured': 'Richardson S, Hirsch JS, Narasimhan M et al (2020) Presenting ' 'characteristics, comorbidities, and outcomes among 5700 patients ' 'hospitalized with COVID-19 in the New York City area. JAMA. ' 'https://doi.org/10.1001/jama.2020.6775', 'DOI': '10.1001/jama.2020.6775'}, { 'key': '5301_CR8', 'doi-asserted-by': 'publisher', 'unstructured': 'Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020; published online May ' '29) Characteristics associated with hospitalisation for COVID-19 in ' 'people with rheumatic disease: data from the COVID-19 Global ' 'Rheumatology Alliance physician-reported registry. Ann Rheum Dis. ' 'https://doi.org/10.1136/annrheumdis-2020-217871', 'DOI': '10.1136/annrheumdis-2020-217871'}, { 'issue': '6', 'key': '5301_CR9', 'doi-asserted-by': 'publisher', 'first-page': '623', 'DOI': '10.1111/j.1464-5491.2006.01861.x', 'volume': '23', 'author': 'JK Yang', 'year': '2006', 'unstructured': 'Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, Sun GZ, Yang GR, Zhang ' 'XL, Wang L, Xu X, Xu XP, Chan JCN (2006) Plasma glucose levels and ' 'diabetes are independent predictors for mortality and morbidity in ' 'patients with SARS. Diabet Med 23(6):623–628', 'journal-title': 'Diabet Med'}, { 'key': '5301_CR10', 'doi-asserted-by': 'publisher', 'unstructured': 'Graef ER, Liew JW, Putman MS, Simard JF, Sirotich E, Berenbaum F, ' 'Duarte-García A, Grainger R, Harrison C, Konig MF, Korsten P, Proulx L, ' 'Richards DP, Robinson PC, Sattui SE, Ugarte-Gil MF, Young KJ, Kim AHJ, ' 'Sparks JA (2020) Festina lente: hydroxychloroquine, covid-19 and the ' 'role of the rheumatologist. Ann Rheum Dis:annrheumdis-2020-217480. ' 'https://doi.org/10.1136/annrheumdis-2020-217480', 'DOI': '10.1136/annrheumdis-2020-217480'}, { 'key': '5301_CR11', 'unstructured': 'Mahevas M, Tran VT, Roumier M et al (2020) No evidence of clinical ' 'efficacy of hydroxychloroquine in patients hospitalized for COVID-19 ' 'infection with oxygen requirement: results of a study using routinely ' 'collected data to emulate a target trial. medRxiv'}, { 'key': '5301_CR12', 'doi-asserted-by': 'publisher', 'unstructured': 'Raef Fadel DO, Morrison AR, Pharm D, Amit Vahia MD, Smith ZR, Pharm D, ' 'Zohra Chaudhry MD, Pallavi Bhargava MD, Joseph Miller MD, Kenney RM, ' 'Pharm D, George Alangaden MD, Mayur S, Ramesh MD, Ford HCOVID-19 ' 'Management Task Force, Early Short Course Corticosteroids in ' 'Hospitalized Patients with COVID-19. Clin Infect Dis:ciaa601. ' 'https://doi.org/10.1093/cid/ciaa601', 'DOI': '10.1093/cid/ciaa601'}, { 'key': '5301_CR13', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30185', 'volume': '395', 'author': 'C Huang', 'year': '2020', 'unstructured': 'Huang C, Wang Y, Li X et al (2020) Clinical features of patients ' 'infected with 2019 novel coronavirus in Wuhan, China. Lancet ' '395:497–506. https://doi.org/10.1016/S0140-6736(20)30185 ' 'pmid:http://www.ncbi.nlm.nih.gov/pubmed/31986264', 'journal-title': 'Lancet'}, { 'key': '5301_CR14', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen X, Zhao B, Qu Y, Chen Y, Xiong J (2020) Detectable serum SARS-CoV-2 ' 'viral load (RNAaemia) is closely correlated with drastically elevated ' 'interleukin 6 (IL-6) level in critically ill COVID-19 patients. Oxford ' 'University Press for the Infectious Diseases Society of America', 'DOI': '10.1101/2020.02.29.20029520'}], 'container-title': 'Clinical Rheumatology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s10067-020-05301-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s10067-020-05301-2/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s10067-020-05301-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 7, 26]], 'date-time': '2021-07-26T23:46:06Z', 'timestamp': 1627343166000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s10067-020-05301-2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7, 27]]}, 'references-count': 14, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2020, 9]]}}, 'alternative-id': ['5301'], 'URL': 'http://dx.doi.org/10.1007/s10067-020-05301-2', 'relation': {}, 'ISSN': ['0770-3198', '1434-9949'], 'subject': ['General Medicine', 'Rheumatology'], 'container-title-short': 'Clin Rheumatol', 'published': {'date-parts': [[2020, 7, 27]]}, 'assertion': [ { 'value': '4 June 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '14 July 2020', 'order': 2, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '17 July 2020', 'order': 3, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '27 July 2020', 'order': 4, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Compliance with ethical standards'}}, { 'value': 'None.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Disclosures'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit